Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: A paired microarray analysis

Molecular Medicine

Volumn 14, Issue 9-10, 2008, Pages 608-617

  DeVoti, James A ^a,b   Rosenthal, David W ^a,b,c   Wu, Rong ^a,d   Abramson, Allan L ^a,d   Steinberg, Bettie M ^a,c,d   Bonagura, Vincent R ^a,b,c,e  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^c Elmezzi Graduate School of Molecular Medicine   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e Division of Allergy/Immunology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA;

ADAPTIVE IMMUNITY; ARTICLE; BENIGN TUMOR; CELL DIFFERENTIATION; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HOST RESISTANCE; HUMAN; HUMAN TISSUE; IMMUNE DYSREGULATION; IMMUNE RESPONSE GENE; INNATE IMMUNITY; LARYNX MUCOSA; LARYNX PAPILLOMATOSIS; MICROARRAY ANALYSIS; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PAPILLOMA; PAPILLOMATOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENT DISEASE; RECURRENT RESPIRATORY PAPILLOMATOSIS; RNA ANALYSIS; STUDENT T TEST; TUMOR GENE; TUMOR GROWTH; UNINDEXED SEQUENCE;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; LARYNGEAL MUCOSA; LARYNGEAL NEOPLASMS; LARYNX; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PAPILLOMA; PROTEINS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 55049137960     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2008-00060.DeVoti     Document Type: Article

References (49)

1. Gissmann LL, et al. (1983). Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. U. S. A. 80:560-3.
2. Mounts P, Shah KV, and Kashima H. (1982) Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc. Natl. Acad. Sci. U. S. A. 79:5425-9.
3. Abramson AL, Steinberg BM, and Winkler B. (1987) Laryngeal papillomatosis: clinical, histopathologic and molecular studies. Laryngoscope 97:678-85.
4. Kashima HB, Leventhal B, and Mounts P. (1985) Papilloma Study Group: scoring system to assess severity and course in recurrent respiratory papillomatosis. In: Papillomavirus: Molecular and Clinical Aspects. Howley H and Booker T (eds.) Alan R Liss, New York. pp. 1-25.
5. Steinman L. (2007) A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13:139-45. Erratum in 13:385
6. Bonagura VR, et al. (1994) Enriched HLA-DQ3 phenotype and decreased class I major histocompatibility complex antigen expression in recurrent respiratory papillomatosis. Clin. Diagn. Lab. Immunol. 1:357-60.
7. Vambutas A, et al. (2004) Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11. J. Infect. Dis. 189:871-9.
8. DeVoti JA, et al. (2004) Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis. Clin. Diagn. Lab. Immunol. 11:538-47.
9. Bonagura VR, Hatam L, DeVoti J, Zeng F, and Steinberg BM. (1999) Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin. Immunol. 93:302-11.
10. Rosenthal DW, DeVoti JA, Schmidtmayerova H, Steinberg BM, and Bonagura VR. (2008) Human papillomavirus causes a TH2-like chemokine predominance in recurrent respiratory papillomatosis (RRP) [abstract]. J. Allergy Clin. Immunol. 121:S15.
11. Vambutas A, Bonagura VR, and Steinberg BM. (2000) Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease. Clin. Diagn. Lab. Immunol. 7:79-85.
12. Bonagura VR, et al. (2004) HLA alleles, IFN-gamma responses to HPV-11 E6, and disease severity in patients with recurrent respiratory papillomatosis. Hum. Immunol. 65:773-82.
13. Langowski JL, et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442:461-5.
14. Langowski JL, Kastelein RA, and Oft M. (2007) Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol. 28:207-12.
15. Zhang P, and Steinberg BM. (2000) Overexpression of PTEN/MMAC1 and decreased activation of Akt in human papillomavirus-infected laryngeal papillomas. Cancer Res. 60:1457-62.
16. Wu R, Coniglio SJ, Chan A, Symons MH, and Steinberg BM. (2007) Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol. Med. 13:143-50.
17. Rangel-Moreno J, et al. (2005) Role of CXC chemokine ligand 13, CC chemokine ligand (CCL) 19, and CCL21 in the organization and function of nasal-associated lymphoid tissue. J. Immunol. 175:4904-13.
18. Veerman KM, et al. (2007) Interaction of the selectin ligand PSGL-1 with chemokines CCL21 and CCL19 facilitates efficient homing of T cells to secondary lymphoid organs. Nat. Immunol. 8:532-9.
19. Takamura K, et al. (2007) Regulatory role of lymphoid chemokine CCL19 and CCL21 in the control of allergic rhinitis. J. Immunol. 179:5897-906.
20. Westermann J, et al. (2007) CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 14:523-32.
21. Forssmann U, Magert HJ, Adermann K, Escher SE, and Forssmann WG. (2001) Hemofiltrate CC chemokines with unique biochemical properties: HCC-1/CCL14a and HCC-2/CCL15. J. Leukoc. Biol. 70:357-66.
22. Shanmugham LN, et al. 2006. Rantes potentiates human macrophage aggregation and activation responses to calcium ionophore (A23187) and activates arachidonic acid pathways. J. Biol. Regul. Homeost. Agents 20:15-23.
23. Bettelli E, Korn T, and Kuchroo VK. (2007) Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 19:652-7.
24. Nakae S, Iwakura Y, Suto H, and Galli SJ. (2007) Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukoc. Biol. 81:1258-68.
25. Huang F, et al. (2007) Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J. Immunol. 179:6504-13.
26. Bettelli E, et al. (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-8.
27. Evans HG, Suddason T, Jackson I, Taams LS, and Lord GM. (2007) Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc. Natl. Acad. Sci. U. S. A. 104:17034-9.
28. Hatam LJ, et al. CD4+Foxp3+CD127+low T-regulatory cells are increased in HPV infected papillomas in patients with recurrent respiratory papillomatosis (RRP) [abstract]. J. Allergy Clin. Immunol. 121:S211.
29. Towne JE, Garka KE, Renshaw BR, Virca GD, and Sims JE. (2004) Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NFkappaB and MAPKs. J. Biol. Chem. 279:13677-88.
30. Barksby HE, Lea SR, Preshaw PM, and Taylor JJ. (2007) The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149:217-25.
31. Berglof ER, et al. (2003) IL-1Rrp2 expression and IL-1F9 (IL-1H1) actions in brain cells. J. Neuroimmunol. 139:36-43.
32. Wang P, et al. (2005) The interleukin-1-related cytokine IL-1F8 is expressed in glial cells, but fails to induce IL-1beta signalling responses. Cytokine 29:245-50.
33. Ramadas RA, et al. (2006) IL-1 Receptor antagonist as a positional candidate gene in a murine model of allergic asthma. Immunogenetics 58:851-5.
34. Chong KT, et al. (2006) High level expression of human epithelial beta-defensins (hBD-1, 2 and 3) in papillomavirus induced lesions. Virol J. 3:75.
35. Rahbar R, et al. (2005) Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 114:289-95.
36. Poetker DM, Sandler AD, Scott DL, Smith RJ, and Bauman NM. (2002) Survivin expression in juvenile-onset recurrent respiratory papillomatosis. Ann. Otol. Rhinol. Laryngol. 111:957-61.
37. Pham TT, Ongkeko WM, An Y, and Yi ES. (2007) Protein expression of the tumor suppressors p16INK4A and p53 and disease progression in recurrent respiratory papillomatosis. Laryngoscope 117:253-7.
38. Mohsenin A, Burdick MD, Molina JG, Keane MP, and Blackburn MR. (2007) Enhanced CXCL1 production and angiogenesis in adenosine-mediated lung disease. FASEB J. 21:1026-36.
39. Moriconi A, et al. (2007) Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J. Med. Chem. 50:3984-4002.
40. Salama I, Malone PS, Mihaimeed F, and Jones JL. (2007) A review of the S100 proteins in cancer. Eur. J. Surg. Oncol. 34:357-64.
41. Foell D, Wittkowski H, Vogl T, and Roth J. (2007) S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukoc. Biol. 81:28-37.
42. Hough CD, Cho KR, Zonderman AB, Schwartz DR, and Morin PJ. (2001) Coordinately upregulated genes in ovarian cancer. Cancer Res. 61:3869-76.
43. Matsumoto K, et al. (2007) Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology 70:602-7.
44. Emberley ED, et al. (2005) The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res. 65:5696-702.
45. Alowami S, Qing G, Emberley E, Snell L, and Watson PH. (2003) Psoriasin (S100A7) expression is altered during skin tumorigenesis. BMC Dermatol. 3:1.
46. Celis JE, et al. (1996) Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J. Urol. 155:2105-12.
47. Madsen P, et al. (1991) Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated in psoriatic skin. J. Invest. Dermatol. 97:701-12.
48. Yang Z, et al. (2001) Proinflammatory properties of the human S100 protein S100A12. J. Leukoc. Biol. 69:986-94.
49. Yang Z, et al. (2007) S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J. Allergy Clin. Immunol. 119:106-14.